CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Recommendation of “Moderate Buy” by Brokerages

CytomX Therapeutics, Inc. (NASDAQ:CTMX) has been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $5.77.

Separately, HC Wainwright reiterated a “neutral” rating on shares of CytomX Therapeutics in a report on Monday, November 11th.

CytomX Therapeutics Price Performance

Shares of NASDAQ:CTMX opened at $1.06 on Monday. The firm’s 50-day moving average is $1.06 and its two-hundred day moving average is $1.27. CytomX Therapeutics has a 1 year low of $0.83 and a 1 year high of $5.85. The firm has a market capitalization of $82.96 million, a PE ratio of 6.24 and a beta of 1.06.

CytomX Therapeutics (NASDAQ:CTMX) last released its earnings results on Thursday, November 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.23. The company had revenue of $33.43 million for the quarter, compared to analyst estimates of $18.92 million. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. During the same period in the prior year, the business earned $0.04 EPS. Analysts expect that CytomX Therapeutics will post -0.05 EPS for the current fiscal year.

Institutional Investors Weigh In On CytomX Therapeutics

Institutional investors have recently modified their holdings of the company. Assenagon Asset Management S.A. increased its holdings in CytomX Therapeutics by 206.0% in the second quarter. Assenagon Asset Management S.A. now owns 1,238,499 shares of the biotechnology company’s stock valued at $1,511,000 after buying an additional 833,825 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of CytomX Therapeutics in the 1st quarter valued at about $57,000. Candriam S.C.A. acquired a new stake in shares of CytomX Therapeutics during the 2nd quarter worth about $256,000. XTX Topco Ltd lifted its stake in CytomX Therapeutics by 382.6% during the second quarter. XTX Topco Ltd now owns 60,586 shares of the biotechnology company’s stock worth $74,000 after purchasing an additional 48,033 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its holdings in CytomX Therapeutics by 1.4% in the second quarter. Acadian Asset Management LLC now owns 2,728,569 shares of the biotechnology company’s stock valued at $3,324,000 after purchasing an additional 37,739 shares in the last quarter. 67.77% of the stock is owned by hedge funds and other institutional investors.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.